Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MindMed logo — MindMed is a clinical-stage biopharma company developing nov...

MindMed

MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders

Founded 2019 United States New York, United States 103 employees Post Ipo Equity Total: $377.63M Biotechnology, Health Care +1

General Information

Company Name MindMed
Founded Year 2019
Location United States New York, United States +2
Founders / Decision Makers
Team member Team member Team member Team member
Employees 103
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when MindMed moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MindMed

MindMed is a clinical-stage biopharmaceutical company founded in 2019 with a mission to address brain health disorders, focusing on psychiatry, addiction, pain, and neurology. The company aims to be a global leader in developing and delivering treatments to improve patient outcomes. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. The company has received a significant $175.00M Post-IPO Equity investment on 07 March 2024 from a consortium of investors including Marshall Wace, Ally Bridge Group, Commodore Capital, Deep Track Capital, Driehaus Capital Management, Janus Handerson, Octagon Capital Advisors, Soleus Capital, Woodline Partners, and Great Point Partners. MindMed's focus on innovative drug candidates targeting the serotonin, dopamine, and acetylcholine systems places it at the forefront of biotechnology, healthcare, and pharmaceutical industries, showcasing its potential to address unmet medical needs and drive advancements in brain health treatments.

Taxonomy: biopharmaceutical, clinical-stage, psychiatry, addiction treatment, neurology, serotonin, dopamine, acetylcholine, psychedelic medicines, substance abuse disorders, drug development pipeline, NASDAQ, NEO Exchange, Psilocybin, LSD

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
07 Mar 2024
Post-IPO Debt •••••• 1
Investor
14 Aug 2023
Post-IPO Equity •••••• - 27 Sep 2022
Post-IPO Equity •••••• 1
Investor
08 Mar 2021
Post-IPO Equity •••••• 3
Investor Investor Investor
14 Dec 2020

View All 11 Funding Rounds

MindMed Alternatives & Competitors

MindMed vs
Canadian Zinc Corporation
Canadian Zinc Corporation

Canadian Zinc Corporation, a company in the development phase, is listed on the Toronto Stock Exchan...

Post Ipo Equity
MindMed vs
Grow Condos Inc
Grow Condos Inc United States

Grow Condos, a publicly traded company under the symbol GRWC: Pink Sheets, targets the cannabis indu...

Post Ipo Equity
Real Estate
Compare MindMed vs Grow Condos Inc
MindMed vs
ICTV Brands, Inc.
ICTV Brands, Inc. United States

ICTV Brands Inc. is an omni-channel consumer marketing and branding company focused on the rapidly g...

Series Unknown
3 employees
Advertising, Retail
Compare MindMed vs ICTV Brands, Inc.
Also compare with: MindMed vs Lifeist Wellness Lifeist Wellness

FAQ About MindMed

MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders
MindMed was founded in 2019.
MindMed is headquartered in New York, United States.
MindMed operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
MindMed has approximately 103 employees.
MindMed has completed 11 funding rounds, raising a total of $377.63M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to MindMed include Canadian Zinc Corporation, Grow Condos Inc, ICTV Brands, Inc., Lifeist Wellness, Great Quest Gold. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MindMed and Canadian Zinc Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MindMed and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy